Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,709,824
  • Shares Outstanding, K 295,850
  • Annual Sales, $ 191,450 K
  • Annual Income, $ -70,220 K
  • 36-Month Beta 1.88
  • Price/Sales 22.67
  • Price/Cash Flow N/A
  • Price/Book 34.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.27 +15.72%
on 01/17/18
32.20 -5.59%
on 01/04/18
+0.93 (+3.16%)
since 12/22/17
3-Month
24.14 +25.93%
on 11/15/17
32.20 -5.59%
on 01/04/18
+3.42 (+12.68%)
since 10/23/17
52-Week
16.72 +81.82%
on 01/31/17
32.50 -6.46%
on 10/16/17
+12.11 (+66.21%)
since 01/23/17

Most Recent Stories

More News
Novartis Announces Positive Results on Migraine Candidate

Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,

NVS : 87.21 (+0.24%)
EXEL : 30.40 (+3.26%)
ABBV : 105.38 (-1.04%)
AMGN : 191.99 (-0.18%)
Look for Shares of Exelixis Inc to Potentially Pullback after Yesterday's 2.28% Rise

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $29.49 to a high of $30.32. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $29.55...

EXEL : 30.40 (+3.26%)
Anthera's Sollpura Strong on Positive Futility in Phase III

Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.

XOMA : 33.28 (-1.65%)
SCMP : 17.95 (+0.28%)
EXEL : 30.40 (+3.26%)
ANTH : 1.54 (+8.45%)
Seattle Genetics' Adcetris Gets EU Nod for Label Expansion

European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.

MRK : 61.70 (+0.73%)
EXEL : 30.40 (+3.26%)
SGEN : 56.76 (+0.83%)
BMY : 63.43 (+0.24%)
Regeneron's Dupixent Receives MHLW Nod for Label Expansion

Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

XOMA : 33.28 (-1.65%)
EXEL : 30.40 (+3.26%)
REGN : 381.71 (+1.56%)
SNY : 43.74 (+1.25%)
BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall

Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.

IDRA : 2.16 (-0.46%)
BCRX : 5.26 (-1.13%)
EXEL : 30.40 (+3.26%)
BMY : 63.43 (+0.24%)
Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks

More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.

TECH : 141.49 (+0.35%)
CELG : 104.55 (+1.59%)
BIVV : 103.16 (-0.61%)
EXEL : 30.40 (+3.26%)
PRTK : 16.15 (-0.31%)
JUNO : 85.86 (-0.16%)
SNY : 43.74 (+1.25%)
ANTH : 1.54 (+8.45%)
Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?

Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?

CELG : 104.55 (+1.59%)
NVO : 57.94 (-0.02%)
EXEL : 30.40 (+3.26%)
AMGN : 191.99 (-0.18%)
JUNO : 85.86 (-0.16%)
SNY : 43.74 (+1.25%)
BIIB : 346.75 (-0.26%)
Bristol-Myers (BMY) Reports Data from CheckMate-142 Study

Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab).

XOMA : 33.28 (-1.65%)
MRK : 61.70 (+0.73%)
EXEL : 30.40 (+3.26%)
BMY : 63.43 (+0.24%)
Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.

AGIO : 79.20 (+1.08%)
CELG : 104.55 (+1.59%)
SCMP : 17.95 (+0.28%)
EXEL : 30.40 (+3.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 31.15
1st Resistance Point 30.78
Last Price 30.40
1st Support Level 29.76
2nd Support Level 29.11

See More

52-Week High 32.50
Last Price 30.40
Fibonacci 61.8% 26.47
Fibonacci 50% 24.61
Fibonacci 38.2% 22.75
52-Week Low 16.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.